ArticleACS omega2025
Aqueous Humor Proteome in RVO-Associated Macular Edema: Analysis during Three Consecutive Conbercept Treatments.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis exploratory study aimed to assess the aqueous humor (AH) proteome in patients with retinal vein occlusion (RVO) and macular edema (ME) receiving three consecutive intravitreal injections of Conbercept, to identify potential molecular pathways, and to generate hypotheses.
methodsLabel-free quantitative liquid chromatography-tandem mass spectrometry was applied to analyze the AH of patients with RVO and ME who underwent three consecutive Conbercept intravitreal injections (IVI) and age-matched controls. The alterations in BCVA, central retinal thickness (CRT), and AH proteins were ascertained through a permutation-based calculation (the false discovery rate was set at 0.05). A repeated-measures analysis determined the most significantly changed protein in the AH (α = 0.05).
resultsCompared to controls, 45 proteins were regulated in the RVO cohort, with 19 and 48 proteins differentially expressed in the branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) subgroups, respectively. The plasma kallikrein (
conclusionsThis exploratory proteomic analysis identified distinct pathway alterations in early RVO pathogenesismetabolic in BRVO and inflammatory in CRVOand common treatment-related changes: plasma kallikrein was downregulated, while desmocollin-3 was up-regulated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.